{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T21:20:16Z","timestamp":1791062416111,"version":"4.1.0"},"reference-count":18,"publisher":"SAGE Publications","issue":"5","license":[{"start":{"date-parts":[[2014,2,12]],"date-time":"2014-02-12T00:00:00Z","timestamp":1392163200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2014,5]]},"abstract":"<jats:p>Objective: To report the use of febuxostat in order to potentiate thiopurines\u2019 metabolism in a patient on azathioprine (AZA) therapy with low metabolite 6-thioguanine nucleotides (6-TGN) levels and elevated metabolite 6-methylmercaptopurine (6-MMP) levels. Case Summary: A 44-year-old woman with a history of anti\u2013signal recognition particle necrotizing myopathy was treated with AZA-allopurinol combination therapy. When she developed an atypical drug-induced hypersensitivity syndrome, allopurinol was replaced by the new xanthine oxidase (XO) inhibitor febuxostat, at a daily dose of 40 mg. Febuxostat-AZA combination was successful with 6-TGN reaching therapeutic levels while 6-MMP levels remained low. After 5 months, she developed similar manifestations that she had presented on AZA-allopurinol combination. Febuxostat and AZA were then stopped. Discussion: AZA and 6-MP are both inactive pro-drugs that undergo a complex metabolic transformation leading to active 6-TGN and potentially hepatotoxic 6-MMP. Some patients with unfavorable thiopurine metabolism might benefit from addition of XO inhibitor allopurinol in order to potentiate 6-TGN and reduce 6-MMP levels. It is likely that febuxostat, via its XO inhibition, would exhibit the same effect on thiopurines\u2019 metabolism. Conclusion: It has been shown that low dose of febuxostat was able to prevent hypermethylation and to potentiate 6-TGN levels in an AZA-treated patient. Thus, febuxostat could be useful in optimizing thiopurines\u2019 metabolism, but more data are needed before this practice can be recommended. The mechanisms by which febuxostat optimizes thiopurines\u2019 metabolism remain to be confirmed. Also, the optimal dose of febuxostat for this use remains to be determined.<\/jats:p>","DOI":"10.1177\/1060028014521389","type":"journal-article","created":{"date-parts":[[2014,2,12]],"date-time":"2014-02-12T23:32:50Z","timestamp":1392247970000},"page":"648-651","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":14,"title":["Febuxostat as a Novel Option to Optimize Thiopurines\u2019 Metabolism in Patients With Inadequate Metabolite Levels"],"prefix":"10.1177","volume":"48","author":[{"given":"Maxime","family":"Dor\u00e9","sequence":"first","affiliation":[{"name":"H\u00f4pital du Sacr\u00e9-Coeur de Montr\u00e9al, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne Julie","family":"Frenette","sequence":"additional","affiliation":[{"name":"H\u00f4pital du Sacr\u00e9-Coeur de Montr\u00e9al, Montreal, Quebec, Canada"},{"name":"University of Montreal, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Marie","family":"Mansour","sequence":"additional","affiliation":[{"name":"H\u00f4pital du Sacr\u00e9-Coeur de Montr\u00e9al, Montreal, Quebec, Canada"},{"name":"University of Montreal, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yves","family":"Troyanov","sequence":"additional","affiliation":[{"name":"H\u00f4pital du Sacr\u00e9-Coeur de Montr\u00e9al, Montreal, Quebec, Canada"},{"name":"University of Montreal, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josiane","family":"B\u00e9gin","sequence":"additional","affiliation":[{"name":"H\u00f4pital du Sacr\u00e9-Coeur de Montr\u00e9al, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2014,2,12]]},"reference":[{"key":"bibr1-1060028014521389","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1H121"},{"key":"bibr2-1060028014521389","doi-asserted-by":"publisher","DOI":"10.1592\/phco.30.6.594"},{"key":"bibr3-1060028014521389","unstructured":"Takeda Uloric (Febuxostat) product monograph 2013. Mississauga, ON: Takeda Pharmaceuticals Canada, Inc; 2013."},{"key":"bibr4-1060028014521389","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-008-0478-6"},{"key":"bibr5-1060028014521389","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2012.05084.x"},{"key":"bibr6-1060028014521389","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2013.06.002"},{"key":"bibr7-1060028014521389","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.7.5.607"},{"key":"bibr8-1060028014521389","doi-asserted-by":"publisher","DOI":"10.1016\/j.crohns.2011.12.003"},{"key":"bibr9-1060028014521389","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2005.02583.x"},{"key":"bibr10-1060028014521389","doi-asserted-by":"publisher","DOI":"10.1016\/j.crohns.2012.12.006"},{"key":"bibr11-1060028014521389","doi-asserted-by":"publisher","DOI":"10.1016\/j.crohns.2012.02.007"},{"key":"bibr12-1060028014521389","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0b013e3182247b45"},{"key":"bibr13-1060028014521389","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20219"},{"key":"bibr14-1060028014521389","doi-asserted-by":"publisher","DOI":"10.1126\/science.2649979"},{"key":"bibr15-1060028014521389","doi-asserted-by":"publisher","DOI":"10.1097\/00007691-199904000-00015"},{"key":"bibr16-1060028014521389","doi-asserted-by":"publisher","DOI":"10.2174\/1871528111312010004"},{"key":"bibr17-1060028014521389","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.110092"},{"key":"bibr18-1060028014521389","doi-asserted-by":"publisher","DOI":"10.1097\/MEG.0b013e3283545ae3"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1060028014521389","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1060028014521389","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1060028014521389","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:14:53Z","timestamp":1777374893000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1060028014521389"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2,12]]},"references-count":18,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014,5]]}},"alternative-id":["10.1177\/1060028014521389"],"URL":"https:\/\/doi.org\/10.1177\/1060028014521389","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,2,12]]}}}